Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue

Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $57.27 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'